These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 8447851

  • 1. General pharmacology of loracarbef in animals.
    Shetler T, Bendele A, Buening M, Clemens J, Colbert W, Deldar A, Helton D, McGrath J, Shannon H, Turk J.
    Arzneimittelforschung; 1993 Jan; 43(1):60-70. PubMed ID: 8447851
    [Abstract] [Full Text] [Related]

  • 2. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. General pharmacology of recombinant human basic fibroblast growth factor.
    Okumura M, Yajima M, Nishimura T, Ikeda H, Nishimori T.
    Arzneimittelforschung; 1996 Jul; 46(7):727-39. PubMed ID: 8842346
    [Abstract] [Full Text] [Related]

  • 6. General pharmacology of beraprost sodium. 2nd communication: effect on the autonomic, cardiovascular and gastrointestinal systems, and other effects.
    Murata T, Murai T, Kanai T, Ogaki Y, Sanai K, Kanda H, Sato S, Kajikawa N, Umetsu T, Matsuura H.
    Arzneimittelforschung; 1989 Aug; 39(8):867-76. PubMed ID: 2510743
    [Abstract] [Full Text] [Related]

  • 7. General pharmacology of insulin lispro in animals.
    Helton DR, Zimmermann JL, Heim A, Jones TW, Turk JA, Kallman MJ.
    Arzneimittelforschung; 1996 Jan; 46(1):91-7. PubMed ID: 8821525
    [Abstract] [Full Text] [Related]

  • 8. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [Abstract] [Full Text] [Related]

  • 9. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S, Ikezono K, Umezato M, Hosoki E, Toba Y, Ishikawa M, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. General pharmacology of the new non-xanthine adenosine A1 receptor antagonist (+)-(R)-[(E)-3-(2-phenylpyrazolo[1,5-a]pyridin-3-yl)acryloyl]-2- piperidine ethanol.
    Terai T, Kusunoki T, Kita Y, Yoshida K, Akahane A, Shiokawa Y, Kohno Y, Horiai H, Mori J, Mine Y, Kohsaka M.
    Arzneimittelforschung; 1996 Feb; 46(2):185-91. PubMed ID: 8720311
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [General pharmacology of T-2588, a new oral cephem antibiotic].
    Hirai S, Kodama T, Hiraiwa T, Abe N, Arai H, Ono S, Omori M, Nakada Y, Hashiba K, Tanada K.
    Jpn J Antibiot; 1986 Apr; 39(4):958-78. PubMed ID: 3761550
    [Abstract] [Full Text] [Related]

  • 14. General pharmacology of nizatidine in animals.
    Bemis K, Bendele A, Clemens J, Deldar A, Gidda J, Hamelink J, Holland D, Lamishaw B, McGrath J, Shannon H.
    Arzneimittelforschung; 1989 Feb; 39(2):240-50. PubMed ID: 2567169
    [Abstract] [Full Text] [Related]

  • 15. General pharmacology of cis-malonato[4R,5R)-4,5-bis-(aminomethyl)-2-isopropyl-1,3- dioxolane]platinum(II).
    Kim DK, Ahn JS, Ryu G, Kim KH, Park CW, Kim MS, Chung MH, Shin SG, Suh YH, Kim YS.
    Arzneimittelforschung; 1994 Sep; 44(9):1080-8. PubMed ID: 7986249
    [Abstract] [Full Text] [Related]

  • 16. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y, Taira N, Fujitani B, Ito T, Kadokawa T.
    Arzneimittelforschung; 1986 Sep; 36(1):55-62. PubMed ID: 3513777
    [Abstract] [Full Text] [Related]

  • 17. General pharmacology of recombinant human tumor necrosis factor. 1st communication: effects on cardiovascular, gastrointestinal, renal and blood functions.
    Nakatsuji K, Kii Y, Fujitani B, Ito T.
    Arzneimittelforschung; 1990 Feb; 40(2 Pt 1):218-25. PubMed ID: 2334464
    [Abstract] [Full Text] [Related]

  • 18. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y, Makino M, Usui C, Takasuna K, Kasai Y, Hirohashi M, Tamura K, Takayama S, Kojima H, Iizuka H.
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [Abstract] [Full Text] [Related]

  • 19. [General pharmacology of T-3262, a new pyridonecarboxylic acid].
    Hirai S, Hiraiwa T, Arai H, Ono S, Tanaka K, Hashiba K, Nakada Y, Goden K, Tanada K, Maekawa M.
    Jpn J Antibiot; 1989 Apr; 42(4):831-53. PubMed ID: 2769937
    [Abstract] [Full Text] [Related]

  • 20. Pharmacology of secoverine, a new spasmolytic agent with specific antimuscarinic properties. Part 2: General pharmacological properties.
    Zwagemakers JM, Claassen V.
    Arzneimittelforschung; 1980 Apr; 30(9):1526-34. PubMed ID: 7193021
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.